Chitin & chitosan

01Overview and value chain

Markers: [EC: Circular Bioeconomy Strategy & REACH Regulation | OECD: bio-materials | Regulator: FDA (US, GRAS), EFSA (EU, Novel Foods), REACH (EU)]

Chitin is the second most abundant biopolymer on Earth after cellulose, forming the shells of crabs, shrimp and lobster, insect exoskeletons, and fungal cell walls; chitosan, its deacetylated derivative, carries a cationic charge in mildly acidic conditions that gives it flocculant, biocidal, biocompatible and film-forming properties unmatched by most other biopolymers. By 2026 the sector has grown from a simple seafood-waste disposal channel into a dedicated biopolymer industry: Tidal Vision’s Tidal Clear platform pairs its ACHPlus hybrid coagulant (alkaline ferric chloride plus precision chitosan formulations) to cut chemical use and sludge in water treatment, while remaining a closed-loop, non-toxic alternative to synthetic polyacrylamide flocculants. On the medical side, Germany’s Heppe Medical Chitosan (HMC) supplies pharmaceutical-grade chitosan and custom oligomers under GMP conditions to European drug developers. Iceland’s Primex, based in Siglufjörður, derives its ChitoClear product line from deep-water shrimp (Pandalus borealis) shells and has extended into cosmetic-grade ChitoCare ingredients for skincare. Belgium’s KitoZyme takes a different sourcing route entirely — fermentation-derived fungal chitosan, certified and marketed as a vegan alternative to synthetic and crustacean-derived polymers for health, beauty and agriculture applications.

The key directions of the chitin/chitosan value chain are:

1. Technical chitin: the semi-finished product from demineralized, deproteinized crustacean shells, used as chitosan feedstock or an animal-feed additive.
2. Industrial (water-treatment-grade) chitosan: moderately deacetylated (75-85%) chitosan used as a biodegradable coagulant/flocculant for industrial and municipal wastewater, removing heavy metals and oils.
3. Agricultural-grade chitosan: used as a seed treatment and foliar spray that acts as an elicitor, activating plants’ natural defense genes against fungal and viral pathogens and reducing chemical-pesticide reliance.
4. High-purity medical/pharma-grade chitosan: ultra-high deacetylation (>95%), minimal ash content (<0.2%) and no detectable protein or endotoxin residue, used in sutures, tissue-engineering scaffolds and controlled-release drug systems.

Sectoral value chain

[Crustacean Shells] ──> [Demineralization & Deproteinization] ──> [Thermochemical Deacetylation]
                 │                              │                                │
        (Seafood-processing waste)    (Purified chitin recovery)        (Conversion to chitosan)
                                                                                  │
       [End Products (Medical, Packaging)] <─── [Reprecipitation & Dialysis] <────┘

Value chain levels

Cross-cutting technologies of the sector:

• Enzymatic deacetylation: an alternative to harsh alkaline hydrolysis using recombinant chitin deacetylases (marine or fungal), operating at mild temperature (37°C) and neutral pH to produce chitosan with tightly controlled acetylation patterns without polymer-chain degradation.
• Deep eutectic solvent (DES) extraction: environmentally benign solvent mixtures (e.g., choline chloride/urea) that remove both calcium and protein from raw shells simultaneously, avoiding mineral acids/alkalis entirely and preserving astaxanthin as a valuable antioxidant byproduct.
• Electrospinning of chitosan nanofibers: drawing ultrafine chitosan fibers (50-200 nm diameter) from a trifluoroacetic-acid solution under a strong electric field, creating highly porous matrices that mimic skin extracellular matrix for accelerated deep-burn healing.

02US

The US leads in chitosan-based packaging innovation and military-grade emergency hemostatic products.

closed-loop water-treatment chitosan, military hemostatic gauze, FDA/EPA regulatory routes

• Tidal Vision: its Tidal Clear platform, including the ACHPlus hybrid coagulant (alkaline ferric chloride plus precision chitosan formulations), reduces chemical use and sludge volume in water treatment as a closed-loop, non-toxic alternative to synthetic polyacrylamide.
• Military hemostatics: the US Department of Defense procures high-purity chitosan-based hemostatic dressings (such as Celox-type bandages), whose positively charged chitosan binds instantly to negatively charged red-blood-cell membranes to form a clot even in severe arterial wounds under hypothermic conditions.
• Regulatory routes: the EPA has certified chitosan as a broad-spectrum biopesticide for organic farming, while the FDA classifies medical-grade chitosan under strict device requirements, demanding biocompatibility testing and shellfish-protein-residue screening to avoid anaphylaxis risk in shellfish-allergic patients.

03CN

China is the global volume leader in crustacean-shell processing, concentrating enormous technical chitin and chitosan capacity in its coastal provinces — no single Chinese producer was confirmed via live sourcing for this article, but the country’s industrial and agricultural chitosan applications are well documented at scale.

Shandong processing scale, industrial wastewater treatment, agricultural chitosan scale-up

• Coastal processing scale: Shandong province concentrates a large share of the world’s chitin and chitosan production capacity, processing shrimp shells sourced from domestic aquaculture and imports from Southeast Asia.
• Industrial wastewater treatment: Chinese textile and electroplating plants use technical chitosan to capture heavy-metal ions (chromium, copper, nickel) and synthetic dyes from effluent, supporting compliance with China’s “Green Mountains, Clean Waters” environmental program.
• Agricultural biostimulant scale-up: Chinese agrochemical producers manufacture water-soluble chitosan oligosaccharides at large volume, sprayed on rice and vegetable crops to improve drought and fungal-disease resistance.

04EU

The EU is the world’s leading center for ultra-pure medical-grade chitosan and circular biodegradable packaging under the bloc’s plastic-reduction strategy.

medical-grade chitosan manufacturing, circular packaging R&D, EFSA plant-protection approval

• Heppe Medical Chitosan (Germany): supplies pharmaceutical-grade chitosan and custom chitosan oligomers under GMP conditions to European drug developers and researchers.
• Primex (Iceland): derives its ChitoClear chitosan line from deep-water shrimp (Pandalus borealis) shells sourced in the North Atlantic, and has extended into cosmetic-grade ChitoCare ingredients for skincare formulations.
• KitoZyme (Belgium): produces fermentation-derived fungal chitosan, certified and marketed as a vegan alternative to synthetic and crustacean-sourced polymers for health, beauty and agricultural applications.
• EFSA approval: the European Food Safety Authority has listed chitosan hydrochloride as an approved “basic substance” for plant protection across the EU, giving farmers a legal alternative to synthetic fungicides in organic agriculture.

05Leading companies and research institutes

06Tech stack and innovations

Modern chitosan production relies on the following equipment and process stack:

1. Continuous demineralization reactors:
   • Crushed shell feedstock is fed continuously into a cascade of titanium stirred reactors dosed with dilute hydrochloric acid; automated pH sensors hold the reaction at pH 1.5-2.0 to prevent premature protein hydrolysis, while the resulting CO2 is captured and calcium chloride is recovered.
2. High-pressure alkaline deacetylation autoclaves:
   • Dry purified chitin is loaded into 316L stainless-steel reactors with 50% NaOH solution, held under up to 3 bar pressure at 110-120°C; conductivity sensors monitor the degree of acetyl-group removal in real time, automatically stopping the reaction at the target parameters.
3. Wet-spinning nonwoven fiber lines:
   • A pressurized medical-grade chitosan/acetic-acid solution is extruded through spinnerets with thousands of 50-micron microholes into an alkaline coagulation bath, instantly forming continuous filaments that are washed, drawn and wound for weaving into hemostatic gauze.

07Value chains and production pipelines

Industrial pipeline of high-purity medical-grade chitosan via controlled thermochemical extraction (ISO 13485/GMP)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Crab shell crushing &  │ ───> │ 2. Demineralization        │
│    washing                 │      │    (dilute HCl)             │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Deacetylation           │ <─── │ 3. Deproteinization        │
│    (NaOH, 110°C)           │      │    (dilute NaOH)            │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Purification,          │ ───> │ 6. Drying & deacetylation │
│    reprecipitation, dialysis│    │    degree control           │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Raw material preparation and crab-shell crushing

Dried king crab (Paralithodes camtschaticus) shells pass through a magnetic separator to remove metal contaminants, are crushed to 2-4mm particle size in a knife mill, washed in hot deionized water to remove residual salt and sand, and dried to under 8% moisture.

Stage 2: Chemical demineralization

Crushed shells are loaded into a titanium demineralization reactor with 1.0M hydrochloric acid (1:10 solid:liquid ratio), reacted at 20°C for 4 hours with continuous stirring; the released CO2 is vented, calcium carbonate fully dissolves, and the product is filtered and washed to neutral pH.

Stage 3: Deproteinization

The desalted shell is transferred to a stainless-steel reactor with 5% sodium hydroxide solution (1:15 ratio), heated to 85°C for 6 hours under vigorous stirring, fully hydrolyzing the protein matrix and removing the astaxanthin pigment; the resulting technical chitin flakes are washed to neutral pH and vacuum-dried to under 5% moisture.

Stage 4: Thermochemical deacetylation

Dry purified chitin is loaded into a deacetylation autoclave with concentrated 50% NaOH (1:20 ratio), sealed under 2 bar pressure and heated to 110°C for 8 hours; for ultra-high deacetylation (>95%), the reaction is halted after 4 hours, the alkali is drained and replaced with a fresh 50% NaOH charge for a further 4 hours, then the hot alkali is drained and the resulting solid chitosan is washed until the filtrate reaches pH 7.0.

Stage 5: Dissolution, filtration, reprecipitation and dialysis

For medical-grade purity, chitosan is dissolved in 2% ultra-pure L-lactic acid at 40°C to form a 1.5% viscous solution, pressure-filtered through a cascade of depth polypropylene filters down to 1-micron pore size, then slowly precipitated with 5% ammonia to pH 8.5, forming a white gel that is washed by tangential-flow ultrafiltration (dialysis) until conductivity drops below 10 microsiemens/cm.

Stage 6: Drying, milling and final quality control

The purified chitosan gel is centrifuged, freeze-dried at -45°C under deep vacuum for 36 hours, then jet-milled in a sterile zone to under 100-micron particle size; QC confirms degree of deacetylation above 95.0% by proton-NMR, dynamic viscosity of a 1% acetic-acid solution, ash content under 0.2%, no detectable protein by Bradford assay, heavy metals under 0.1 ppm, and bacterial endotoxins under 0.1 EU/mg by LAL test before packaging for pharmaceutical supply.